“I have great confidence in the production capacity and quality of the production of that plant, since it is already the third,” said the commander in chief, Fidel Castro, at the opening ceremony of the facility on December 3. of 1993.
The IFV, a research, development and production entity, was founded in 1991 after a group of Cuban scientists presented a vaccine against meningitis (Neisseria meningitidis), commercially known as VA-MENGOC-BC®.
The introduction of the drug had a great impact by eliminating the epidemic that mainly affected children and adolescents.
The name of the institution pays tribute to the Cuban epidemiologist, Carlos J. Finlay, a native of the province of Camagüey, who verified that a biological agent that transmits yellow fever was capable of spreading the disease from a sick subject to a healthy one.
The discovery was fundamental to fight the disease and for subsequent research into what is known today as vector-borne diseases.
Among the center’s main contributions, the creation of the Soberana 02 and Soberana Plus vaccines and the Soberana 01 candidate against Covid-19 stand out in the last two years, but throughout history other developed immunogens guarantee their scientific value.
In statements to Prensa Latina, the vice director of Industrial Operations, Roselyn Martínez, explained that the IFV already has six production plants, with platforms capable of obtaining polysaccharides, products through chemical synthesis and whole cell components.
This means that as an institution we have a broad capacity to face large-scale production of different types of immunogens, Martínez highlighted.
We can not only source the active pharmaceutical ingredients used for these products but also reach the final stage.
The world of biotechnology is very dynamic, it is continually being updated and regulatory standards become more demanding every day, and that imposes investment processes on us to renew the technology, commented the expert.
Currently, the institution manages a closed cycle of products that range from research, development, production, marketing and distribution, highlighted the specialist.
oda/river
2023-12-03 13:11:00
#Finlay #Vaccine #Institute #decades #making #history #Prensa #Latina
